Profile of olaparib in the treatment of advanced ovarian cancer

Olaparib is a poly(ADP-ribose) polymerase inhibitor that received accelerated approval from the US Food and Drug Administration as monotherapy for patients with germline BRCA mutations and ovarian cancer treated with three or more prior lines of chemotherapy. This article summarizes the mechanism of...

Descripción completa

Detalles Bibliográficos
Autores principales: Chase, Dana M, Patel, Shreya, Shields, Kristin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847603/
https://www.ncbi.nlm.nih.gov/pubmed/27186080
http://dx.doi.org/10.2147/IJWH.S55906
_version_ 1782429246691475456
author Chase, Dana M
Patel, Shreya
Shields, Kristin
author_facet Chase, Dana M
Patel, Shreya
Shields, Kristin
author_sort Chase, Dana M
collection PubMed
description Olaparib is a poly(ADP-ribose) polymerase inhibitor that received accelerated approval from the US Food and Drug Administration as monotherapy for patients with germline BRCA mutations and ovarian cancer treated with three or more prior lines of chemotherapy. This article summarizes the mechanism of poly(ADP-ribose) polymerase inhibition, therapeutic profile and uses of olaparib, and current and ongoing literature pertaining to olaparib in advanced ovarian cancer.
format Online
Article
Text
id pubmed-4847603
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-48476032016-05-16 Profile of olaparib in the treatment of advanced ovarian cancer Chase, Dana M Patel, Shreya Shields, Kristin Int J Womens Health Review Olaparib is a poly(ADP-ribose) polymerase inhibitor that received accelerated approval from the US Food and Drug Administration as monotherapy for patients with germline BRCA mutations and ovarian cancer treated with three or more prior lines of chemotherapy. This article summarizes the mechanism of poly(ADP-ribose) polymerase inhibition, therapeutic profile and uses of olaparib, and current and ongoing literature pertaining to olaparib in advanced ovarian cancer. Dove Medical Press 2016-04-18 /pmc/articles/PMC4847603/ /pubmed/27186080 http://dx.doi.org/10.2147/IJWH.S55906 Text en © 2016 Chase et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Chase, Dana M
Patel, Shreya
Shields, Kristin
Profile of olaparib in the treatment of advanced ovarian cancer
title Profile of olaparib in the treatment of advanced ovarian cancer
title_full Profile of olaparib in the treatment of advanced ovarian cancer
title_fullStr Profile of olaparib in the treatment of advanced ovarian cancer
title_full_unstemmed Profile of olaparib in the treatment of advanced ovarian cancer
title_short Profile of olaparib in the treatment of advanced ovarian cancer
title_sort profile of olaparib in the treatment of advanced ovarian cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847603/
https://www.ncbi.nlm.nih.gov/pubmed/27186080
http://dx.doi.org/10.2147/IJWH.S55906
work_keys_str_mv AT chasedanam profileofolaparibinthetreatmentofadvancedovariancancer
AT patelshreya profileofolaparibinthetreatmentofadvancedovariancancer
AT shieldskristin profileofolaparibinthetreatmentofadvancedovariancancer

Ejemplares similares